O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND)

Autor:	Pier Luigi Zinzani, Bruce Feinberg, Maurizio Frezzato, Günter Fingerle-Rowson, Gilles Salles, Anna Maria Barbui, Nathan Fowler, Sumeet Ambarkhane, Dario Marino, Erika Meli, Sascha Tillmanns, Claudia Castellino, Stephan Parche, Grzegorz S. Nowakowski, Thomas D. Rodgers, Mark Winderlich
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty business.industry Internal medicine medicine Hematology business Transplant ineligible Lenalidomide medicine.drug
Zdroj:	Annals of Oncology. 32:S293
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.05.547
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f4beccf8b4b0f2700b1b092bc045b9d9 https://doi.org/10.1016/j.annonc.2021.05.547 Zobrazit plný text záznamu